Prasugrel Beats Ticagrelor in Diabetic Stent Patients
Prasugrel’s Ascendancy: Personalized Antiplatelet Therapy for Diabetics Signals a New Era in Stent Care Nearly 38 million Americans live with diabetes, and this population faces a significantly heightened risk of cardiovascular events, particularly following percutaneous coronary intervention (PCI) with stent placement. For years, clinicians have relied on antiplatelet medications like Ticagrelor and Prasugrel to prevent … Read more